An Investigation into LGBTQ+ Programming and Climate at a Midwest Master’s Comprehensive University

An investigation exploring how a mid-sized Midwest master\u27s comprehensive university promotes programming and DEI efforts toward queer students on campus. Student engagement within these areas and the needs of queer students are explored through survey responses

Analyzing consumer protection for gamblers across different online gambling operators: a descriptive study

Over the last decade, online gambling has been steadily increasing both in availability and in popularity. Player protection has been in the centre of gambling regulation, and various initiatives have been set in place by some online gambling companies in order to ensure responsible gambling and harm minimisation. The aim of the present exploratory study was to evaluate how online gambling operators protect and minimize harm for their consumers (i.e., their gambling clientele). In order to evaluate the responsible gambling initiatives aiding player protection, the 50 most advertised online gambling websites were examined in relation to their responsible gambling practices (including which responsible gambling tools the operator offered, the presence or absence of a responsible gambling page, problem gambling self-assessment test, age verification procedures, etc.). The findings demonstrated that although most operators engage in at least some responsible gambling practices, there is wide inconsistency amongst different online gambling operators. To evaluate customer service communication, one of the research team posed as a potential problem gambler and collated all verbatim interaction. Again, the findings demonstrated wide inconsistencies between online gambling operators. It is concluded that while some online gambling operators appear to be socially responsible, there are a number of areas where further improvement is needed (e.g., age verification, customer service feedback, direct marketing to players)

Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting

Multiple Myeloma (MM) is a hematologic malignancy characterized by a wide clinical and biological heterogeneity leading to different patient outcomes. Various prognostic tools to stratify newly diagnosed (ND)MM patients into different risk groups have been proposed. At baseline, the standard-of-care prognostic score is the Revised International Staging System (R-ISS), which stratifies patients according to widely available serum markers (i.e., albumin, β 2-microglobulin, lactate dehydrogenase) and high-risk cytogenetic abnormalities detected by fluorescence in situ hybridization. Though this score clearly identifies a low-risk and a high-risk population, the majority of patients are categorized as at “intermediate risk”. Although new prognostic factors identified through molecular assays (e.g., gene expression profiling, next-generation sequencing) are now available and may improve risk stratification, the majority of them need specialized centers and bioinformatic expertise that may preclude their broad application in the real-world setting. In the last years, new tools to monitor response and measurable residual disease (MRD) with very high sensitivity after the start of treatment have been developed. MRD analyses both inside and outside the bone marrow have a strong prognostic impact, and the achievement of MRD negativity may counterbalance the high-risk behavior identified at baseline. All these techniques have been developed in clinical trials. However, their efficient application in real-world clinical practice and their potential role to guide treatment-decision making are still open issues. This mini review will cover currently known prognostic factors identified before and during first-line treatment, with a particular focus on their potential applications in real-world clinical practice

Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients

Multiple myeloma (MM) mostly affects elderly patients, which represent a highly heterogeneous population. Indeed, comorbidities, frailty status and functional reserve may vary considerably among patients with similar chronological age. For this reason, the choice of treatment goals and intensity is particularly challenging in elderly patients, and it requires a multidimensional evaluation of the patients and the disease. In recent years, different tools to detect patient frailty have been developed, and the International Myeloma Working Group frailty score currently represents the gold standard. It identifies intermediate-fit and frail patients requiring gentler treatment approaches compared to fit patients, aiming to preserve quality of life and prevent toxicities. This subset of patients is underrepresented in clinical trials, and studies exploring frailty-adapted approaches are scarce, making the choice of therapy extremely challenging. Treatment options for intermediate-fit and frail patients might include dose-adapted combinations, doublets, and less toxic combinations based on novel agents. This review analyzes the available tools for the assessment of frailty and possible strategies to improve the discriminative power of the scores and expand their use in real-life and clinical trial settings. Moreover, it addresses the main therapeutic challenges in the management of intermediate-fit and frail MM patients at diagnosis and at relapse

Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma

Immunotherapy is the latest innovation for the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) entered the clinical practice and are under evaluation in clinical trials. MAbs can target highly selective and specific antigens on the cell surface of MM cells causing cell death (CD38 and CS1), convey specific cytotoxic drugs (antibody-drug conjugates), remove the breaks of the immune system (programmed death 1 (PD-1) and PD-ligand 1/2 (L1/L2) axis), or boost it against myeloma cells (bi-specific mAbs and T cell engagers). Two mAbs have been approved for the treatment of MM: the anti-CD38 daratumumab for newly-diagnosed and relapsed/refractory patients and the anti-CS1 elotuzumab in the relapse setting. These compounds are under investigation in clinical trials to explore their synergy with other anti-MM regimens, both in the front-line and relapse settings. Other antibodies targeting various antigens are under evaluation. B cell maturation antigens (BCMAs), selectively expressed on plasma cells, emerged as a promising target and several compounds targeting it have been developed. Encouraging results have been reported with antibody drug conjugates (e.g., GSK2857916) and bispecific T cell engagers (BiTEs®), including AMG420, which re-directs T cell-mediated cytotoxicity against MM cells. Here, we present an overview on mAbs currently approved for the treatment of MM and promising compounds under investigation

Hymn to the heroes of Malta

Ġabra ta’ poeżiji u proża li tinkludi: Alla fil-ħolqien ta’ Ġużè Agius Bonello – Is-sena u l-bniedem ta’ Ġużè Ellul-Mercer – Li tiżra’ taħsad ta’ Vic. Apap – Huwa ta’ Gino Muscat-Azzopardi – Żewġ friefet ta’ Vincent Caruana – Iċ-ċagħka ta’ Ġużè Borg – Warda midbiela ta’ C. Gauci – It-tfajla tas-sulfarini ta’ Albert M. Cassola – L-aħħar traduzzjoni ta’ May Butcher qabel ma mietet – Hymn to the heroes of Malta.N/